Printer Friendly

NEORX APPOINTS ROBERT SCHROFF AS VICE PRESIDENT & GENERAL MANGER, CARDIOVASCULAR PRODUCTS

 SEATTLE, Jan. 7 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced the appointment of Robert W. Schroff, Ph.D., M.B.A., to the newly created position of vice president, general manager, cardiovascular products. Dr. Schroff has served as director, Business Development and Analytical Laboratories and has been responsible for several of the company's corporate collaborations. Prior to that, he headed NeoRx's Immunological Assessment Laboratory, and then became director of Clinical Research, where he managed initial trials of the company's OncoTrac (R) and Rhenex (R) products.
 Dr. Schroff received his Ph.D., in Immunology from Bowman Gray School of Medicine and did post-doctoral research in clinical immunology at UCLA, where he was a key member of the team that first identified Acquired Immunodeficiency Syndrome (AIDS) that is now known to be caused by the infection with HIV.


Before joining NeoRx in 1985, he spent several years at the National Cancer Institute in its Biological Response Modifiers Program.
 "Under Dr. Schroff's leadership, NeoRx has opened a new area of product development in cardiovascular disease," said Paul Abrams, M.D., J.D., NeoRx's president and CEO. "With his guidance, our scientists have discovered a compound that shows efficacy in a swine animal model or restenosis (closure) of arteries following balloon angioplasty. This appointment signifies NeoRx's greater commitment to this product area. The combination of Dr. Schroff's scientific acumen and his business experience make him the ideal choice for this new role."
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA for two OncoTrac (R) cancer imaging products and has completed a phase III trial for a third. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in pre-clinical testing.
 -0- 1/7/93
 /CONTACT: Robert M. Littauer, vice president, chief financial officer of NeoRx, 206-286-2519; or Anthony J. Russo, Ph.D. or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for NeoRx/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU: PER

AH-LR -- NY051 -- 2652 01/07/93 11:59 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 7, 1993
Words:355
Previous Article:NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
Next Article:JOEL KURTZMAN NAMED EXECUTIVE EDITOR AT HARVARD BUSINESS REVIEW
Topics:


Related Articles
NEORX ACQUIRES PRE-TARGETING TECHNOLOGY FROM STANFORD UNIVERSITY
NEORX DECLARES DIVIDEND
NEORX APPOINTS JOHN RENO AS VICE PRESIDENT, RESEARCH & DEVELOPMENT
NEORX REPORTS FIRST QUARTER 1993 RESULTS
NEORX PROMOTES ROBERT LITTAUER TO SENIOR VICE PRESIDENT
NEORX PROMOTES JEFFREY MILLER TO SENIOR VICE PRESIDENT
NEORX REPORTS SECOND QUARTER 1993 RESULTS
NEORX APPOINTS JACK L. BOWMAN TO BOARD OF DIRECTORS; NUMBER OF BOARD MEMBERS INCREASES TO TEN
NEORX REPORTS 1994 FIRST QUARTER RESULTS
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF VERLUMA(TM), SMALL CELL LUNG CANCER IMAGING AGENT DEVELOPED BY NEORX

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters